Ruxolitinib (JAKAFI)
Kinase Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.
$3.38B in CY2024 Part D spend280K claims · 62K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Ruxolitinib used for?
Ruxolitinib is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Ruxolitinib?
No. Ruxolitinib is brand-only with no generic equivalents currently in market.
How much does my plan pay for Ruxolitinib?
Across 329 Part D plans, Ruxolitinib averages $34.01/unit (NADAC). Lowest available: $34.01/unit. Highest in distribution: $34.01/unit.
Is Ruxolitinib on the FDA shortage list?
No. Ruxolitinib is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.